This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once-daily simeprevir 150 mg + sofosbuvir 400 mg, with and without ribavirin 1000 mg. Primary endpoint was proportion of subjects with week 12 sustained virologic response (SVR12). Thirty-three subjects without cirrhosis were randomized 1:1:1 into three arms (stratified by genotype/subtype and Q80K): Arm 1, simeprevir + sofosbuvir + ribavirin, 12 weeks; Arm 2, simeprevir + sofosbuvir, 12 weeks; Arm 3, simeprevir + sofosbuvir, 24 weeks; 13 additional subjects (two with cirrhosis, 11 without cirrhosis) entered Arm 3. All 46 subjects received at least one dose of study drug; median age, 60 years; 73.9% male; 80.4% White; 71.7% genotype/subtype 1a [12 (36.4%) of these had Q80K]; median 4.5 years post-transplant. Among randomized subjects, SVR12 was achieved by 81.8% in Arm 1, 100% in Arm 2, and 93.9% in Arm 3; two subjects did not achieve SVR12: one viral relapse (follow-up week 4; Arm 1) and one missing follow-up week 12 data. In total, five subjects had a serious adverse event, considered unrelated to treatment per investigator. Simeprevir exposure was increased relative to the nontransplant setting, but not considered clinically relevant. Simeprevir + sofosbuvir treatment, with or without ribavirin, was efficacious and well tolerated (ClinicalTrials.gov Identifier: NCT02165189).
Introduction
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and liver transplantation [1] [2] [3] . Compared with conventional interferon-based therapies [4] [5] [6] and boceprevir/telaprevir-based triple therapies [7] [8] [9] [10] [11] [12] , newer direct-acting antiviral agents have been shown to improve outcomes for liver transplant recipients with recurrent HCV infection [13] [14] [15] [16] [17] [18] [19] . In one study of 34 postliver transplant recipients without cirrhosis, treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for 24 weeks resulted in a sustained virologic response 12 weeks after the end of treatment (SVR12) rate of 97% [13] ; an SVR12 rate of 95% was seen in another study (n = 53) evaluating treatment with daclatasvir + sofosbuvir + ribavirin [19] . In a third study (n = 229), ledipasvir/sofosbuvir + ribavirin for 12 or 24 weeks demonstrated SVR12 rates ranging from 96% to 98% in subjects without cirrhosis or with Child-Turcotte-Pugh (CTP) class A cirrhosis, 85% to 88% in subjects with CTP class B cirrhosis and 60% to 75% in subjects with CTP class C cirrhosis [18] . Despite such favourable outcomes, all approved regimens require the use of ribavirin, which has been associated with safety/tolerability concerns, such as anaemia, fatigue, headache, nausea and hyperbilirubinemia [14, [20] [21] [22] . In addition, the side effects of ribavirin may result in substantial healthcare costs (e.g. laboratory testing, clinic visits, medication) [23] .
Simeprevir is a once-daily, oral, HCV NS3/4A protease inhibitor approved in the nontransplant setting for the treatment of chronic HCV genotype 1 infection as part of combination antiviral therapy [24, 25] . Retrospective studies of simeprevir and sofosbuvir (HCV NS5B nucleotide polymerase inhibitor), with or without ribavirin, in HCV genotype 1-infected liver transplant recipients have demonstrated favourable efficacy and safety profiles over a 12-week treatment period [15] [16] [17] 26, 27] . The vast majority (73-100%) of subjects in these studies did not receive treatment with ribavirin; SVR12 rates ranged from 88% to 94%. In a real-world setting (HCV-TARGET registry), simeprevir and sofosbuvir treatment for 12 or 24 weeks, with or without ribavirin, in postliver transplant recipients showed an SVR12 rate of 88% [28] .
In this phase 2 clinical study (GALAXY; ClinicalTrials.gov Identifier: NCT02165189), the efficacy and safety of simeprevir in combination with sofosbuvir, with or without ribavirin, were evaluated in postorthotopic liver transplant recipients with recurrent HCV genotype 1 infection. The emergence of resistance-associated HCV genotype variants and the pharmacokinetics of simeprevir and sofosbuvir were also assessed. These are the first prospective, multicenter data to be reported on postliver transplant recipients treated with simeprevir and sofosbuvir, with or without ribavirin.
Materials and methods

Study design and population
This was a phase 2, prospective, multicenter, randomized, open-label study that enrolled nonpregnant adults who were ≥18 years of age with recurrent HCV genotype 1 infection and an HCV RNA level >10 000 IU/ml at baseline (study dates: 11 August 2014 to 10 November 2015). Subjects must have had a primary orthotopic liver transplant (living or deceased donor) ≥6 months to 15 years before enrollment and were required to be on stable immunosuppression for ≥3 months before screening. Subjects' renal function, as measured by the Cockcroft Gault formula, must have been >30 ml/min. Assessment of liver fibrosis (liver graft biopsy or non-invasive procedure [29]) within 12 months of or at the screening visit, except for subjects with a diagnosis of cirrhosis, was required. Key exclusion criteria included receiving treatment with a direct-acting antiviral drug for HCV infection (prior treatment with interferon or peginterferon, with or without ribavirin, was allowed if completed ≥3 months before screening); hepatic decompensation; and HCV NS3 resistance-associated mutations identified as conferring resistance to simeprevir, except Q80K.
Initially, 33 subjects without cirrhosis were enrolled and randomized 1:1:1 using an interactive voice or web response system into one of three treatment arms; the randomization was balanced using randomly permuted blocks and was stratified by HCV genotype/subtype and NS3 polymorphism (genotype/subtype 1a with Q80K versus genotype/subtype 1a without Q80K versus genotype/ subtype 1b). The study controlled for the use of ribavirin; the three treatment arms were as follows: Arm 1, oncedaily simeprevir 150 mg + once-daily sofosbuvir 400 mg + weight-based ribavirin (1000 mg daily dose for subjects weighing <75 kg; 1200 mg for subjects weighing ≥75 kg) for 12 weeks; Arm 2, once-daily simeprevir 150 mg + once-daily sofosbuvir 400 mg for 12 weeks; Arm 3, once-daily simeprevir 150 mg + once-daily sofosbuvir 400 mg for 24 weeks. Upon completion of randomization, enrolment into Arm 3 was opened to all eligible subjects, regardless of the presence of cirrhosis, until a total of 46 subjects were enrolled; this allowed subjects with cirrhosis to enter the study and receive the recommended 24 weeks of treatment [24, 25] . For all subjects, the screening period was a maximum of 6 weeks and treatment was followed by a 12-week post-treatment follow-up period. Study drugs were discontinued for subjects with viral breakthrough. Choice of immunosuppressant was at the investigator's discretion, excluding cyclosporine due to a potential pharmacokinetic interaction with simeprevir [24, 25] . See Supporting Information for further study design and population details.
The study protocol was reviewed by an institutional review board. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Subjects provided written informed consent to participate in the study.
Efficacy assessments
The primary efficacy endpoint was the proportion of subjects who achieved SVR12. Secondary efficacy endpoints were on-treatment virologic response at weeks 2, 4, 8 and 12 (all subjects) and weeks 16, 20 and 24 (subjects in Arm 3); the proportion of subjects who achieved sustained virologic response 4 weeks after the end of treatment (SVR4); and the incidence of virologic breakthrough and relapse. In addition, subgroup analyses were performed for SVR12 rates based on subject characteristics, including the presence of baseline HCV polymorphisms (NS3 Q80K and NS5A positions of interest; Supporting Information) and use of gastric acid-reducing agents. The latter were of interest because they may have an effect on antiviral agent pharmacokinetics [30] .
Resistance monitoring
Samples were collected at baseline and at the time of virologic failure during therapy to monitor for the emergence of HCV resistance-associated variants, with sequencing of HCV NS3, NS5A and NS5B polymorphisms at baseline and NS3 and NS5B resistanceassociated variants at the time of failure (Supporting Information).
Pharmacokinetic assessments
Pharmacokinetic sampling of simeprevir and GS-331007 (the major sofosbuvir metabolite [31] ; hereinafter referred to as 'sofosbuvir' for simplicity) trough levels occurred on days 28, 56 and 84 for all subjects and also on Day 168 for subjects in Arm 3. The following parameters were assessed: trough plasma concentration (C trough ), maximum plasma concentration (C max ), average steady-state plasma concentration (C ss,av ), and area under the concentration-time curve from time of administration to 24 h postdose (AUC 24 h ). The model-predicted relationship between creatinine clearance at baseline and the central clearance of sofosbuvir, and the relationship between creatinine clearance at baseline and exposure to sofosbuvir (smoothing line computed using loess smoothing, implemented in R-software) were also evaluated.
Blood samples for the determination of immunosuppressant plasma concentrations were collected twice during the first week of treatment, weekly during the next 3 weeks, and per local institutional protocol thereafter. Immunosuppressant dose adjustments during therapy were also described.
Safety assessments
Safety evaluations included monitoring of adverse events (AEs; for severity grading, see Supporting Information), clinical laboratory tests, vital sign measurements and physical examinations. Diagnosis of rejection was to be made by a local pathologist per institution protocol.
Patient-reported outcomes
Patient-reported outcomes (PROs) were assessed using two validated instruments: the EuroQoL 5-Dimensions (EQ-5D) questionnaire [32] and the Hepatitis C Symptom and Impact Questionnaire version 4 (HCV-SIQv4), a new PRO tool designed specifically for HCV-infected subjects (Supporting Information).
Statistical analyses
The intent-to-treat (ITT) population was defined as all subjects who took at least one dose of study drug. Within the ITT population, randomized subjects were evaluated for efficacy and PRO outcomes. Pharmacokinetics and safety were evaluated in all ITT subjects. SVR12 rates were tabulated per treatment arm. For the determination of sample size, with a target SVR12 rate of 80%, 11 subjects would have allowed the SVR12 rate to be estimated in arms 1 and 2 with a two-sided 95% confidence interval (CI; calculated using a normal approximation with continuity correction) width of 50.8%; thus, 80% (46.3%, 97.1%) and 23 subjects in Arm 3 would have allowed the SVR12 rate to be estimated with a two-sided 95% CI width of 35.3%, thus 80% (58.2%, 93.6%).
Secondary endpoints were summarized using descriptive statistics; SVR4, viral breakthrough, and viral relapse were tabulated per treatment arm. Relevant changes in viral sequence in the HCV NS3 and NS5B regions were summarized. Pharmacokinetic analyses included all subjects who underwent pharmacokinetic sampling at any point during the study. Descriptive statistics are provided for the pharmacokinetic parameters of immunosuppressants, simeprevir and sofosbuvir; for simeprevir and sofosbuvir, parameters were analysed using a Bayesian feedback analysis (Supporting Information). PRO endpoints were analysed using descriptive statistics; mean and median changes from baseline are reported.
Results
Study population
A total of 66 individuals were screened; 20 of these individuals were excluded due to not meeting ≥1 of the inclusion criteria, while 46 were enrolled in the study and took at least one dose of study drug (Fig. 1) . Among all subjects, the median (range) age was 60.0 (49-68) years and the majority were male (73.9%) and 
Efficacy
On-treatment virologic response over time among randomized subjects is shown in Fig. 2a . SVR12 was achieved by 31 of 33 randomized subjects (93.9%), including nine of 11 (81.8%) in Arm 1, 11 of 11 (100%) in Arm 2 and 11 of 11 (100%) in Arm 3 (Fig. 2b) ; the same virologic response rates were observed at the SVR4 time point. One subject did not achieve SVR12 due to viral relapse (at follow-up week 4; see below) and another for nonvirologic reasons (suicide).
For randomized subjects who had HCV genotype/ subtype 1a infection and Q80K polymorphism data, the SVR12 rate was 100% (9/9; 95% CI, 66.4-100%) for those with the Q80K polymorphism and 85.7% (12/14; 95% CI, 57.2-98.2%) for those without. The SVR12 rate was 90.0% (18/20; 95% CI, 68.3-98.8%) for subjects with an NS5A polymorphism and 100% (11/11; 95% CI, 71.5-100%) for those without. The SVR12 rate was 95.0% (19/20; 95% CI, 75.1-99.9%) for subjects who used gastric acid-reducing agents and 92.3% (12/13; 95% CI, 64.0-99.8%) for those who did not.
No subjects experienced viral breakthrough. One subject in Arm 1 experienced viral relapse at the follow-up week 4 time point. This subject was a 53-year-old White male with a body mass index of 29 kg/m 2 , baseline viral load of 4 130 000 IU/ml, HCV genotype/subtype 1a without NS3 Q80K and METAVIR score F2. It had been 7.7 years since transplant and the subject was treatment-experienced with prior response categorized as 'no response'; there were no emerging HCV NS3 or NS5B mutations at the time of failure. No other subjects had resistance testing performed. 
Pharmacokinetic assessments
Exposures to both simeprevir and sofosbuvir were similar across treatment arms among all subjects (Table 2) . A correlation between sofosbuvir exposure and creatinine clearance was observed; central clearance of sofosbuvir increased with increasing creatinine clearance at baseline, and exposure to sofosbuvir (AUC/ C max ) increased with decreasing creatinine clearance (Fig. 3) .
Safety
Overall, most subjects (97.8%) reported an AE during the treatment phase; AEs were balanced across treatment groups (Table 3 ). The most common AEs (>25% of total population) during treatment were headache (37.0%) and fatigue (34.8%). Five (10.9%) subjects had serious AEs, including one that was fatal (suicide); none were considered by the investigator to be related to study drug. Two AEs occurred during treatment that were grade ≥2 in severity and considered possibly related to simeprevir: fatigue and increased gamma-glutamyltransferase. One transplant rejection occurred at follow-up week 12 in Arm 3. Of note, this subject's tacrolimus plasma level fell from 13.8 lg/l at baseline to 3.2 lg/l at the time of rejection. Treatment-induced resolution occurred within 6 days. Four (8.7%) subjects had an AE of photosensitivity (one subject in Arm 2 and three subjects in Arm 3); all events were grade 1 in severity. Three (6.5%) subjects, all in Arm 1, had anaemia; no growth factors were used for treatment. There were four laboratory parameters for which at least one subject had an abnormality with grade 3 severity, including amylase level (two subjects; one each in arms 2 and 3), gamma-glutamyltransferase (one subject; Arm 3), hyperbilirubinemia (one subject; Arm 1) and hyperglycaemia (one subject; Arm 3). There were no grade 4 laboratory abnormalities.
Tacrolimus plasma levels over time are shown in Fig. 4 . A dose adjustment of immunosuppressants (any time during the study) occurred in 15 of 46 (32.6%) subjects: five in Arm 1, one in Arm 2 and nine in Arm 3. For one subject in Arm 3, mycophenolate mofetil was discontinued at screening, and tacrolimus was continued unchanged. For two subjects, either the original or new dose was not known (but both were counted as having a dose adjustment). Apart from these dose adjustments, there were no other changes in immunosuppressant regimens. For the two subjects who did not achieve SVR12, one committed suicide and one had viral relapse.
Patient-reported outcomes
The mean HCV-SIQv4 overall body system score at baseline was similar across treatment arms for randomized subjects, and there were minimal changes from baseline to follow-up week 12 (Table S1 ). At baseline, the mean EQ-5D visual analog scale (VAS) score was comparable across treatment arms (Table S2 ). These scores fluctuated over time; the changes were not considered clinically important, with the exception of a small improvement in EQ-5D VAS score at follow-up week 12 for subjects in Arm 3. Median changes from baseline over time are shown in Fig. S1 . Overall, there were no clear patterns of improvement or worsening in scores over time or differences between treatment arms in PRO data.
Discussion
GALAXY is the first prospective, multicenter study that evaluated simeprevir and sofosbuvir treatment, with or without ribavirin, in the transplant setting. This regimen was efficacious in liver transplant recipients with recurrent HCV genotype 1 infection, consistent with results in a nontransplant setting [33] . SVR12 was achieved by 81.8% of subjects in Arm 1, 100% in Arm 2 and 100% in Arm 3. The relatively lower SVR12 rate in Arm 1 versus arms 2 and 3 was due to missing data from one subject (9.1%). The efficacy of simeprevir in this population was further supported by on-treatment virologic response data. No subjects had viral breakthrough, and only one subject (Arm 1) had viral relapse. For these subjects, the majority of whom did not have cirrhosis, similarly high rates of SVR12 were observed in those with HCV genotype/subtype 1a regardless of the presence of Q80K, consistent with results in the nontransplant setting [33] .
It is clinically important that all subjects (11/11) treated with a ribavirin-free regimen of simeprevir and sofosbuvir for 12 weeks achieved SVR12 because most liver transplant recipients tolerate ribavirin poorly and some cannot tolerate ribavirin at any dose [14, 21] . Furthermore, simeprevir and sofosbuvir, with or without ribavirin, is an HCV NS5A inhibitor-free regimen; as NS5A inhibitors have a low barrier to resistance and variants tend to persist, this regimen may be an option for individuals with HCV NS5A variants [34] [35] [36] . Notably, most GALAXY subjects had an HCV NS5A polymorphism and the presence of these polymorphisms did not have a substantial impact on SVR12 achievement.
Evaluation of potential pharmacokinetic interaction between antiviral agents and commonly used *In total, 152 plasma samples from 46 subjects were available for analysis (of the 159 samples in the data set, two were below the lower limit of quantitation and five were excluded because the intake time of the dose taken prior to the sample was missing). †In total, 153 plasma samples from 46 subjects were available for analysis (of the 159 samples in the data set, one was below the lower limit of quantitation and five were excluded because the intake time of the dose taken prior to the sample was missing.
concomitant medications is important, and for posttransplant recipients, immunosuppressant use is of particular interest. In a previous study of postliver transplant recipients (SATURN), simeprevir exposure was increased 581% during concomitant cyclosporine A use; based on this, cyclosporine A is not recommended for coadministration with simeprevir [24] . The same study showed a 185% increase in simeprevir exposure with concomitant tacrolimus use, but this result was not considered clinically significant [24] . Based on these findings, the current study did not allow for use of cyclosporine A. The GALAXY study is the first to describe steadystate simeprevir and sofosbuvir exposures in postliver transplant recipients with HCV genotype 1 infection. Subjects' exposures to these agents were similar regardless of treatment arm; however, compared with similar data collected in a nontransplant setting (COSMOS study) [33] , exposures were numerically higher (simeprevir AUC 24 h values were 26 820 and 44 300 ngÁh/ml, and sofosbuvir AUC 24 h values were 10 801 and 17 884 ngÁh/ml, in COSMOS and GALAXY, respectively). Given the large variability in the current study, these exposure differences were not considered clinically relevant. It is possible that the increase in simeprevir exposure may be due, in part, to a mild pharmacokinetic interaction between simeprevir and tacrolimus [24] . The lack of a clinically relevant change in sofosbuvir exposure is consistent with previous findings in post-transplant recipients and healthy volunteers [14, 31] .
Simeprevir and sofosbuvir treatment, with or without ribavirin, was generally well tolerated, consistent with previous reports in this population [15] [16] [17] 26, 27] . Safety outcomes were comparable across arms, and not unexpectedly, anaemia was only observed in subjects treated with ribavirin [15, 26, 27] . There were few serious AEs and only two subjects had an AE that was grade ≥2 and considered possibly related to simeprevir. One transplant rejection occurred at follow-up week 12; consistent with this, the subject's tacrolimus level had markedly decreased from baseline to the time of rejection. A gradual downward trend in tacrolimus levels was observed in subjects using tacrolimus, similar to what has been noted in another study of simeprevir and sofosbuvir in this patient population [15] . Decreased tacrolimus levels may be explained by the reduced tacrolimus exposure with simeprevir coadministration that was previously observed in healthy volunteers [37] . It is also possible that subjects' liver function improved during effective HCV therapy, leading to HCV RNA clearance and subsequently increased tacrolimus metabolism [38] . Caution should be used when interpreting these tacrolimus pharmacokinetic results given the small numbers of subjects with available data at each time point and the overlapping CIs.
PRO endpoints were evaluated to describe the severity of symptoms associated with HCV or its treatment and health-related quality of life before and after treatment during the current GALAXY study. At baseline, subjects reported overall symptom severity and healthrelated quality of life measures that were similar to what's been reported in the nontransplant setting for HCV genotype 1-infected subjects without cirrhosis or with compensated cirrhosis [39] . In that study of nontransplant subjects, symptom scores improved with simeprevir and sofosbuvir treatment by the follow-up week 12 visit, sometimes by amounts considered clinically important. In the post-transplant GALAXY population, HCV-SIQv4 overall body system scores did not change relative to baseline, and the median change in EQ-5D VAS scores indicated an improvement that was slightly less than the value that has been shown to be clinically important in all cases except in Arm 3 subjects at the follow-up week 12 time point, at which point a small but clinically significant improvement was observed.
A limitation of the current study is the small sample size, which necessitated descriptive statistics and limited comparisons between treatment groups. For example, there was one subject who had missing data in the randomized population; this subject represented 9.1% of *None of the serious AEs were considered to be possibly related to study drug by the investigator. The serious AEs were as follows: Arm 1, device-related infection and completed suicide; Arm 3, small intestinal obstruction (randomized subgroup), abdominal hernia (nonrandomized subgroup) and prostate cancer (nonrandomized subgroup). †One subject committed suicide, considered unrelated to study drug by the investigator. ‡AEs were fatigue and increased gamma-glutamyltransferase. §One subject committed suicide and discontinued all three study medications; a second subject discontinued ribavirin due to anaemia. ¶Reported by >10% of subjects in total population by preferred term. **One (2.2%) subject had a photosensitivity reaction AE by preferred term, and a total of four (8.7%) subjects had a photosensitivity condition AE of clinical interest (including the following preferred terms: photosensitivity reaction and sunburn). All events were grade 1 in severity. † †A total of ten (21.7%) subjects had a rash AE of clinical interest (including the following preferred terms: rash, sunburn, cutaneous vasculitis, palmar erythema, photosensitivity reaction, and vesicular rash). All events were grade 1 in severity.
the Arm 1 population and significantly impacted the SVR12 rate in this treatment group (as noted above).
Another limitation is that the majority of subjects had less advanced disease (METAVIR score F0-F2), which has been associated with higher SVR12 rates in previous studies in HCV genotype 1-infected liver transplant recipients [13, 15, 16] . However, it is also possible that disease severity was underestimated in some cases, as assessment of liver fibrosis could have occurred up to 12 months prior to screening. In summary, the GALAXY study demonstrated the efficacy and safety of simeprevir and sofosbuvir treatment, with or without ribavirin, for 12 or 24 weeks in postorthotopic liver transplant recipients with recurrent HCV genotype 1. These regimens may be clinically important options for individuals with NS5A variants and, importantly, 100% of subjects treated with simeprevir and sofosbuvir for 12 weeks achieved SVR12, suggesting that this regimen may be adequate for individuals without cirrhosis. Further study is warranted to determine whether this therapy is also efficacious in patients with cirrhosis. 
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article:
Appendix S1. Materials and methods. Table S1 . HCV-SIQv4 Overall Body System Score:
Change From Baseline (randomized ITT) a . Table S2 . EQ-5D VAS Baseline Scores (randomized  ITT) a . Figure S1 . Median change from baseline in EQ-5D VAS score over time (randomized ITT). a,b
